Kornimate/medical-research-clean huggingface dataset:
a comprehensive wellness program (sky) to mitigate physician burnout

Conditions: Depression; Anxiety; Stress; Insomnia; Optimism; Interpersonal Disengagement; Professional Fulfillment; Work Exhaustion; Self-reported Medical Errors; Physician Burnout

Summary: the primary objective of the study was to determine whether the yoga-based breathing and meditation program sky could improve wellness indicators in currently practicing physicians. the hypothesis of this study is that sky is effective in reducing anxiety and depression, increasing subjective optimism, and reducing physician burnout in healthy, actively practicing physicians.

physicians are exposed to high stress and strain that results in burnout, affecting not only them, their families, patients, but the whole healthcare system. thus there is an urgent need to develop methods to increase resiliency of physicians. a comprehensive yoga breathing and meditation-based online program (sudarshan kriya yoga, or sky) is a potential approach to mitigate physician burnout. this is a randomized clinical trial assessing the potential efficacy of sky compared to a stress management education (sme) training as control, conducted online. both groups received training for three consecutive days, 1,5 hours per day, through group video conference. active physicians participated in the study from november 2021 to march 2022. of the 280 physicians who showed interest and prescreened, 238 were eligible and randomized to receive either the sky or the control intervention.

Eligibility criteria:
inclusion criteria: * actively working physicians without any chronic disease with documented interest in being part of a study to evaluate breath/meditation-derived exercises and a willingness to do some form of relaxation exercises every day for 8 weeks. exclusion criteria: * presence of psychiatric illness or other major illnesses, such as bipolar disorder, post-traumatic stress disorder (ptsd), schizophrenia or schizoaffective disorder, uncontrolled hypertension, lung disease, liver disease, cancer, or heart disease; maintaining a regular mind-body program practice such as meditation, yoga, and breathing techniques.

Keywords: physician burnout medical doctor burnout stress depression wellness meditation breathing exercise
periodontal disease prediction system

Conditions: Periodontal Diseases

Summary: the purpose of this study was to develop a periodontal disease prediction software and a patient-based gingival recession simulator for clinical practice aiming at improving oral hygiene motivation of patients with periodontal problems.

periodontal disease prediction (pdp) software has three components: a) data loading window (dlw) b) three-dimensional mouth model (3dm) and c) periodontal attachment loss indicator (pli). demographic and clinical examinations of 1057 volunteers were recorded to dlw. an unsupervised machine learning k means clustering analysis was used to categorize the data obtained from the study population and identified the periodontal risk groups. an intraoral scanner was utilized to capture direct optical intraoral data of a patient and transferred to the 3dm. the intraoral model went under two algorithm steps for obtaining a recessed model. first, gingival curves separating gingiva and tooth were extracted using a dijkstra's algorithm. limit curves determining boundaries of recessed regions in the intraoral model were then obtained using gingival curves. the gingival recession was then mimicked by losing gingiva and disappearing tooth roots at proper locations in the intraoral model and additionally, the final four different 3 dimensional recessed model (maxilla, mandibula, anterior teeth and posterior teeth) belonging to the same patient were scored based on the similarity to the real gingival recession by 25 periodontology specialist via online survey.

Eligibility criteria:
inclusion criteria: * age greater than 18 years, * periodontal status ranging from no clinical periodontal disease (\<10% with bleeding on probing) to periodontitis (stage i to iv) * patients having at least one teeth in each quadrant were included. exclusion criteria: * patients undergoing orthodontic treatment and using anti-inflammatory drugs were excluded.

Keywords: gingival recession oral hygiene motivation computer-aided design
reinforcement of the pancreas in distal pancreatectomy (replay)

Conditions: Distal Pancreatectomy (DP)

Summary: despite an improvement regarding morbidity and mortality since 30 years, especially in expert centers, pancreatic surgery remains currently associated to a significant postoperative morbidity reaching more than 60%. regarding distal pancreatectomy (dp), the main complication following surgery is the occurrence of postoperative pancreatic fistula (pf) which may be able to lead an increased risk of bleeding, gastroparesis and finally a longer hospital stays. the main risk factors associated to the occurrence of pancreatic fistula are represented by the texture of the pancreatic parenchyma (soft pancreas) and the caliber of the main pancreatic duct (\<3mm). looking for new means of reducing the occurrence of pancreatic fistula is a priority in pancreatic surgery and a genuine public health issue. currently, no formal recommendations concerning the optimal technical for closure of the distal stump in dp are available. in fact, manual closing by elective suturing or stapling of the main pancreatic duct give similar results. the use of a reinforcing stapling potentially represents a simple way to decrease the occurrence of pancreatic fistula and requires evaluation by a prospective randomized study.


Eligibility criteria:
inclusion criteria: * all patients who undergo dp whether made by open or laparoscopic surgery * patients 18 years of age or older, * benefiting from a social security scheme, * having given his free, informed and written consent. exclusion criteria: * history of pancreatic abdominal surgery * severe co-morbidity type renal failure requiring hemodialysis, unbalanced diabetes, major respiratory insufficiency, heart failure ≥ stage 3 nyha; * persons of full age who are subject to legal protection, persons deprived of liberty. * pregnant or nursing women * patients participating in or participating in another study
establishing the collaborative care model of traditional chinese medicine and western medicine-pediatric atopic dermatitis

Conditions: Atopic Dermatitis

Summary: in taiwan, there are many patients suffer from pediatric atopic dermatitis. because of the clinical characteristic of repetitive and scratchy, which will affect the patients' quality of life and lead to the medical heavy budget. tcm may play an important role in this disease and help patient to improved their health. in this project, we aim to establish a collaborative care model of tcm and western medicine, to achieve the multiple goal in clinical treatment, research and medical training. by establishing a collaborative care model, including the chinese medicine doctor and western medicine doctor, nurses, pharmacists and case managers, to cooperative satisfy the patient needed in the medical service, to improve the clinical presentation, patients'quality of life, and reduce exposure to corticosteroid. besides, we can also build a training environment and reduce medical cost in long term purpose. furthermore, by establishing a collaborative care model, we can provide a medical education and training opportunity to educate the medical student and clinician the necessary knowledge of pediatric atopic dermatitis by caring patients and learning from clinical case. according to the above training program, we not only aim to strengthen the competitiveness of chinese medicine doctor in taiwan, but also make the western medicine doctors comprehend the tcm characteristic and may find out the even more opportunity to cooperate in clinical practice. to make this collaborative care model as a beginning milestone of cooperation between chinese medicine and western medicine.


Eligibility criteria:
inclusion criteria: * age 0-18 * meets the hanifin and rajka diagnostic criteria * scorad score ≧ 25 exclusion criteria: * drug abuse * pregnent or lactating women * mental or behavioral abnormalities * allergic to the ingredients of the test regimen * any potentially life-threatening disease or dysfunctional organ system l
ultrasonic markers for myocardial fibrosis and prognosis in aortic stenosis

Conditions: Aortic Valve Stenosis; Myocardial Fibrosis

Summary: this study is part of a research project in which new ultrasound-based techniques will be examined to improve clinical decision making for patients with aortic stenosis. these patients could develop increased amounts of myocardial fibrosis. this fibrosis is associated with the patients' prognosis. fibrosis can be evaluated with magnetic resonance imaging (mri), which unfortunately is quite expensive and not easily available. ultrasound-based parameters will be developed for the assessment of the amounts of myocardial fibrosis, especially in the left ventricle. then it will be examined whether these parameters can predict the patients magnitude of fibrosis and check for association with the patients prognosis. mri will serve as a gold standard for quantification of myocardial fibrosis. the new echocardiographic techniques and parameters are expected to provide new insights in the interplay between aortic stenosis and left ventricular function, and to ultimately improve the care for patients with aortic stenosis. the present study's objectives are: * quantify the level of myocardial fibrosis in mild, moderate, and severe aortic stenosis compared with a healthy population. * evaluate the patients outcome after one and three year of follow-up


Eligibility criteria:
inclusion criteria: * able to undergo protocolled investigations * patients: mild, moderate or severe as exclusion criteria: * renal insufficiency * previously myocardial infarction (ecg, echocardiogram or hospital record) * severe valvular heart disease (except patients) * other cardiac disease known to cause myocardial fibrosis * severe hypertension * other medical conditions deterring protocolled investigation and follow-up * other medical conditions affecting 5-yrs prognosis (cancer, pulmonary disease) * severely reduced image-quality (echocardiography and mri)

Keywords: myocardium predictive value of tests prognosis clinical decision-making heart ventricles echocardiography
evaluation of the influence of statins and proton pump inhibitors on clopidogrel antiplatelet effects

Conditions: Coronary Artery Disease

Summary: there is conflicting evidence in the literature suggesting that the use of proton pump inhibitors (ppis), and/or some statins can interfere with clopidogrel antiplatelet effect and result in adverse cardiovascular outcomes in patients treated with coronary artery stents and dual antiplatelet therapy. the primary aim of the study is to determine the effect of various currently used ppi on platelet aggregation in patients undergoing percutaneous coronary intervention (pci) and treated with dual antiplatelet therapy. the secondary aim of the study is to evaluate how statins and 2c19\*2 polymorphism modulate the effect of ppi on clopidogrel efficacy.


Eligibility criteria:
inclusion criteria: * subject must be 18 years of age or older * bare metal stent implantation * discharged with dual antiplatelet therapy for at least 60 days * written informed consent exclusion criteria: * patients who do not consent to participate in the study * premenopausal women not using contraceptive methods or without a negative pregnancy test in the past week * patients treated or planned to be treated with oral anticoagulants * present treatment with or clear indication for treatment with a ppi or h2 antagonists * allergy or intolerance to study medications including ranitidine, proton pump inhibitors, atorvastatin, rosuvastatin, aspirin and/or clopidogrel * patient treated with a strong cyp2c19 interacting drug * history of a bleeding diathesis, or evidence of active abnormal bleeding within 30 days before enrollment * history of intracranial hemorrhage or intracranial surgery in the last 3 months * history of gastro-intestinal ulcers in the last 3 months * any serious illness or any condition that the investigator feels would influence the impact of this therapy on the subject * known platelet count \< 100000/mm3 at time of enrollment or within 24 hours prior to enrollment

Keywords: ranitidine pantoprazole esomeprazole omeprazole atorvastatin rosuvastatin statin clopidogrel resistance antiplatelet therapy coronary artery disease percutaneous coronary intervention stent clopidogrel proton pump inhibitors drug interactions drug resistance genetic polymorphism
fexofenadine (allegra®) in healthy adults who have been identified as slow metabolizers for desloratadine

Conditions: Allergic Rhinitis

Summary: to evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. to evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers.


Eligibility criteria:
inclusion criteria: * healthy, adult, non-smoking males and females between 18 and 55 years of age, inclusive; whites of european or north american heritage and blacks of african or caribbean heritage. exclusion criteria: * any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study. * historical, clinical, or laboratory evidence of liver disease including but not limited to transaminase activity concentrations \>2.5 times the upper limit of the reference range. * active peptic ulcer disease or a history of gastrointestinal surgery within the last 6 months. * history of cholecystectomy. * history of malignancy within the last 5 years (except basal cell carcinoma, which must be in remission for at least 6 months prior to the study. * pregnant or lactating females or females of childbearing potential who are unwilling to use reliable, medically accepted methods of contraception. if subjects who are not sexually active with members of the opposite sex become so during the study, these subjects must agree to use a medically accepted method of contraception. * history of hypersensitivity or intolerability to either desloratadine or fexofenadine or other antihistamines. * treatment with other antihistamines in the last month before study entry. * use of any prescription or over-the-counter medications or dietary/herbal supplements (with the exception of oral or implanted contraceptives) within 1 week or 5 half-lives, whichever is longer, of the study. * history of alcoholism or drug abuse within 12 months of the study. * ingestion of alcohol within 1 week of the first dose of study medication. * ingestion of grapefruit or grapefruit juice within 1 week of the study and a willingness to abstain from the consumption of grapefruit or grapefruit juice for the duration of the study. * participation in any other clinical trial or use of an investigational product within 30 days of entry into the study.
rbc lifespan measurement in diabetic children

Conditions: Diabetes; Red Blood Cell Survival

Summary: hba1c, a measure of mean blood glucose over the lifespan of a red blood cell (rbc), is a marker of increasing importance both for assessing glycemic control in children with known diabetes and for the diagnosis of diabetes in children. hba1c has demonstrated poor reliability in diagnosis and management of pediatric diabetes and the most plausible reason for this unreliability is that the reference ranges of hba1c were established based on 120-day rbc lifespan observed in adults, without considering the rbc lifespan difference between children and adults. the proposed studies will for the first time determine rbc lifespan in diabetic children

screening visit: there will be one screening visit before the study. we will do some blood tests that will determine if the subjects can be in this study. if the subject is qualify, he/she will be asked to return for the following scheduled visits. study visit 1: we will draw a small amount of subject's blood from the iv. the study subject's blood will then be marked with biotin. we will give back the subject's blood marked with biotin through iv within 4 to 6 hours. endotoxin analysis (conducted pre-infusion) and bacterial culture analysis (conducted post-infusion) will be performed. twenty minutes after the blood transfusion, we will draw blood from the iv. after that, we will take out the iv and the subject can go home. all follow-up study visits: the subject will have a study visit 24 hours after receiving blood marked with biotin. after that, the subject will have a clinic visit every 7-10 days. these visits will end when we can no longer find the biotin marked blood cells in the subject's blood. this is expected to be approximately 12 weeks later. at these visits, we will draw blood and also collect all blood glucose results in the past 7-10 days. after the study visits are completed, there will be one follow-up visit 4-6 months after the subject receives the biotin marked rbcs. we will draw about 0.25 ml of blood. continuous glucose monitoring and hba1c determination-- we will monitor continuous glucose concentrations throughout the study. this will be accomplished by setting up freestyle libre pro continuous glucose monitoring (cgm) device for each study subject. in addition, hba1c will be measured once in the middle of the study (likely visit 6) and in the end of the study (likely visit 12).

Eligibility criteria:
inclusion criteria: * children with either type1 or type 2 diabetes between 4-18 years old exclusion criteria: * consumption of biotin supplements or raw eggs within 30 days; * history of gastrointestinal blood loss; * heart failure ; * active viral or bacterial infection; * hemoglobinopathy; * prior history of liver disease with transaminases more than 3 times the upper limit of normal for age; * uncontrolled thyroid disease; * anemia (whole blood hct\<33); * history of renal disease (prior serum creatinine more than \>1.5 mg/dll); * detectable antibody to biotin.

Keywords: diabetic children rbc lifespan
dietary fatty acid composition and obesity-related metabolic abnormalities

Conditions: Overweight/Obese Women

Summary: individuals have a significant capacity to adapt to different environments by changing their core metabolic pathways. this adaptation is especially important in regards to diet. epidemiological research over the last several decades have shown that diets high in saturated fats have a greater ability to cause insulin resistance and the 'metabolic syndrome' while diets low in saturated fats (or a so called 'mediterranean diet), reduces the risk for cardiovascular disease. in humans, experimental diets high in unsaturated fats, as compared to high carbohydrate or high saturated fat diets, result in increased insulin sensitivity and improved lipid profiles. in this application, the investigators propose to systematically assess the effects of two diets enriched in either saturated or unsaturated fatty acids and determine the cellular and molecular mechanisms of the apparent increase in insulin sensitivity. the investigators hypothesize that individuals will 'adapt' to the different diets and the investigators will be able to generate predictive alterations in gene expression and metabolites that underlie the alterations in metabolism. in parallel, the investigators will test the ability of these different diets to affect the release of gastrointestinal hormones that may be critical to modulation of appetite.


Eligibility criteria:
inclusion criteria: * premenopausal females with bmi range of 25-32 kg/m2 exclusion criteria: * evidence of metabolic or cardiovascular disease, fasting plasma glucose concentration \> 125mg/dl, abnormal ekg, hyperlipidemia (plasma triglyceride concentration \> 150mg/dl), pregnancy, hematocrit \<34%

Keywords: high fat diet treatment insulin sensitivity
scandinavian urethroplasty study

Conditions: Urethral Stricture

Summary: a multicentre, prospective, randomized study comparing bulbar urethroplasty with excision and primary anastomosis or with an onlay grafting procedure using buccal mucosa.

the study is a prospective, randomized study to compare two common techniques of urethroplasty used to treat bulbar urethral strictures. one technique is excision of the stricture and end-to-end anastomosis of the urethra. the other technique is an onlay grafting procedure with buccal mucosa where the corpus spongiosum is not divided. the study is designed to compare complications of sexual and penile function, and is not powered to compare the success rates of the two techniques. the primary endpoint will be degree of erectile dysfunction and penile complications. the secondary endpoint will be restricturing leading to reoperation, and other complications.

Eligibility criteria:
inclusion criteria: patient with bulbar urethral stricture, length estimated by urethrography or endoscopy ≤ 2 cm patient is able and willing to sign informed consent patient is able and willing to complete all study requirements exclusion criteria: previous open urethroplasty previous hypospadia surgery previous surgery for congenital curvature or mb peyronie previous pelvic irradiation therapy known grave psychiatric disorder haemophilia or other clotting disorders that cause bleeding diathesis use of medication to increase erectile function, such as pde5-inhibitors and intracavernous injections, during the study any condition or situation, which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study

Keywords: operative technique
study of effectiveness of lovastatin to prevent radiation-induced rectal injury

Conditions: Prostate Cancer

Summary: lovastatin may protect against late effects of radiation therapy in patients with prostate cancer

oral lovastatin will be given at the dose of 20 mg/day with evening meal beginning on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the first day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate * planned treatment with radiation therapy to include external beam and/or brachytherapy with curative intent (total dose ≥60 gy). a portion of the rectum must receive at least 60 gy. * age at least 18 years * karnofsky performance status (kps) ≥ 70 * no history of prior radiotherapy to the prostate or rectum * history of prior malignancy, if likely to live at least 4 years, is acceptable. * no evidence of distant metastases * patients may be taking an hmg-coa-reductase inhibitor, but to be eligible, they must be able to be changed to lovastatin 20 mg/day, with the permission of their prescribing physician. * creatine kinase \< 5 times upper normal limit * sufficient renal function defined as calculated creatinine clearance ≥ 30ml/min * transaminases \< 3 times upper normal limit exclusion criteria: * planned abdomino-perineal resection after radiotherapy * contraindication to an hmg-coa-reductase inhibitor * major medical or psychiatric illness, which in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up. * currently taking an inhibitor of cytochrome p450 3a4 * active liver or muscle disease

Keywords: prostate cancer radiation therapy lovastatin rectal injury